CtDNA Analysis on Osimertinib in FLAURA and AURA3 trials

Jarushka Naidoo shared a post on X about an article by Jhanelle Gray et al. titled “Longitudinal Analyses of Circulating-Tumor DNA for Detection of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Progression During Treatment: Data From FLAURA and AURA3” published on Journal of Thoracic Oncology.

Authors: Jhanelle E. Gray, Aleksandra Markovets, Thanyanan Reungwetwattana, Margarita Majem, Naoyuki Nogami, Nir Peled, Jong-Seok Lee, Byoung Chul Cho, Busayamas Chewaskulyong, Tom John, Ji-Youn Han, Martin Sebastian, Alexander Todd, Yuri Rukazenkov, Carl Barrett, Juliann Chmielecki, Siow Ming Lee, Suresh S. Ramalingam, Ryan Hartmaier.

“Longitudinal ctDNA Analysis on Osimertinib in FLAURA and AURA3 trials:

– ctDNA PD preceded RECIST by 2.6-3.4m

Interesting, but the APPLE trial Jordi Remon asks the key question- does treatment switch at ctDNA PD impact survival? Answer: No.”

Source: Jarushka Naidoo/X

Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland.

She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials.

She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.